Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00314288 · ClinicalTrials.gov registry record · Phase 2
Sarizotan in Parkinson Patients With L-dopa-induced Dyskinesia
A Phase 2 study, sponsored by EMD Serono.
- Completed
- Registry status
- Phase 2
- Development phase
- 360
- Enrollment target
NCT00314288 is a Phase 2 study that has completed, run by EMD Serono. The registered enrollment target is 360 participants.
The verdict
NCT00314288, a Phase 2 study, has completed, sponsored by EMD Serono.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 360 participants
- Enrollment target
Study Summary
The primary purpose of the study is to investigate the anti-dyskinetic effect of several doses of sarizotan in Parkinson patients in order to generate information on the dose-response relationship (dose-finding).
Interventions
- DRUG Sarizotan HCl
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 360 participants |
| Start Date | 2002-07 |
| Est. Completion | 2003-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00314288
The ClinicalTrials.gov registry entry for NCT00314288 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 360 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EMD Serono, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sarizotan HCl is the first listed.
NCT00314288 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00314288 about?
NCT00314288 is a clinical study titled "Sarizotan in Parkinson Patients With L-dopa-induced Dyskinesia". The primary purpose of the study is to investigate the anti-dyskinetic effect of several doses of sarizotan in Parkinson patients in order to generate information on the dose-response relationship (dose-finding).
What is the current status of trial NCT00314288?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 360 participants. The study started on 2002-07. Estimated completion is 2003-07.
What interventions are being tested in trial NCT00314288?
The interventions under investigation include: Sarizotan HCl (DRUG).
Who is sponsoring clinical trial NCT00314288?
This trial is sponsored by EMD Serono, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.